Is Dare Bioscience Stock a Good Investment?
Dare Bioscience Investment Advice | DARE |
- Examine Dare Bioscience's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Dare Bioscience's leadership team and their track record. Good management can help Dare Bioscience navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Dare Bioscience's business and its evolving consumer preferences.
- Compare Dare Bioscience's performance and market position to its competitors. Analyze how Dare Bioscience is positioned in terms of product offerings, innovation, and market share.
- Check if Dare Bioscience pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Dare Bioscience's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Dare Bioscience stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Dare Bioscience is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Dare Bioscience Stock
Researching Dare Bioscience's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.17. Dare Bioscience last dividend was issued on the 20th of July 2017. The entity had 1:12 split on the 1st of July 2024.
To determine if Dare Bioscience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dare Bioscience's research are outlined below:
| Dare Bioscience generated a negative expected return over the last 90 days | |
| Dare Bioscience has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 9.78 K. Net Loss for the year was (4.05 M) with loss before overhead, payroll, taxes, and interest of (13.22 M). | |
| Dare Bioscience has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Dar Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAYSildenafil Cream |
Dare Bioscience Quarterly Cash And Short Term Investments |
|
Dare Bioscience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dare Bioscience. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dare Bioscience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Dare Bioscience's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Dare Bioscience's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-14 | 2024-03-31 | -0.06 | -0.07 | -0.01 | 16 | ||
2023-11-09 | 2023-09-30 | -0.1 | -0.09 | 0.01 | 10 | ||
2023-05-11 | 2023-03-31 | -0.1 | -0.09 | 0.01 | 10 | ||
2021-08-12 | 2021-06-30 | -0.16 | -0.18 | -0.02 | 12 | ||
2022-03-31 | 2021-12-31 | -0.15 | -0.18 | -0.03 | 20 | ||
2020-03-27 | 2019-12-31 | -0.18 | -0.21 | -0.03 | 16 | ||
2024-03-28 | 2023-12-31 | -0.1 | -0.06 | 0.04 | 40 | ||
2022-11-10 | 2022-09-30 | -0.12 | -0.08 | 0.04 | 33 |
Know Dare Bioscience's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Dare Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dare Bioscience backward and forwards among themselves. Dare Bioscience's institutional investor refers to the entity that pools money to purchase Dare Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hanson Mcclain Inc | 2025-03-31 | 1.7 K | Tower Research Capital Llc | 2025-03-31 | 1.4 K | Ifs Advisors, Llc | 2025-06-30 | 950 | Sbi Securities Co Ltd | 2025-03-31 | 575 | Bank Of America Corp | 2025-03-31 | 87.0 | Mather Group, Inc. | 2025-03-31 | 84.0 | Advisor Group Holdings, Inc. | 2025-03-31 | 25.0 | Jpmorgan Chase & Co | 2025-03-31 | 19.0 | Caldwell Sutter Capital Inc | 2025-03-31 | 17.0 | Vanguard Group Inc | 2025-03-31 | 328.3 K | Amh Equity Ltd | 2025-03-31 | 164.3 K |
Dare Bioscience's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.95 M.Market Cap |
|
Dare Bioscience's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (47.65) | (45.27) | |
| Return On Assets | (0.18) | (0.19) |
Determining Dare Bioscience's profitability involves analyzing its financial statements and using various financial metrics to determine if Dare Bioscience is a good buy. For example, gross profit margin measures Dare Bioscience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dare Bioscience's profitability and make more informed investment decisions.
Please note, the presentation of Dare Bioscience's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dare Bioscience's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Dare Bioscience's management manipulating its earnings.
Evaluate Dare Bioscience's management efficiency
Dare Bioscience has return on total asset (ROA) of (0.8698) % which means that it has lost $0.8698 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.9469) %, meaning that it created substantial loss on money invested by shareholders. Dare Bioscience's management efficiency ratios could be used to measure how well Dare Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.0007, whereas Return On Tangible Assets are forecasted to decline to (0.19). At present, Dare Bioscience's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 21.1 M, whereas Net Tangible Assets are forecasted to decline to about 16.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.71) | (0.74) | |
| Tangible Book Value Per Share | (0.71) | (0.74) | |
| Enterprise Value Over EBITDA | (3.42) | (3.59) | |
| Enterprise Value Multiple | (3.42) | (3.59) | |
| Enterprise Value | 12.1 M | 11.5 M |
The strategic initiatives led by Dare Bioscience's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.137 |
Basic technical analysis of Dare Stock
As of the 30th of July, Dare Bioscience shows the Variance of 17.38, standard deviation of 4.17, and Mean Deviation of 2.45. Dare Bioscience technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Dare Bioscience information ratio, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Dare Bioscience is priced favorably, providing market reflects its regular price of 2.48 per share. Please also check Dare Bioscience jensen alpha, which is currently at (0.19) to verify the company can sustain itself at a future point.Dare Bioscience's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dare Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dare Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dare Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dare Bioscience's Outstanding Corporate Bonds
Dare Bioscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Dare Bioscience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Dare bonds can be classified according to their maturity, which is the date when Dare Bioscience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Dare Bioscience's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Dare Bioscience's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | 1.09 | |||
| Mean Deviation | 2.45 | |||
| Coefficient Of Variation | (2,021) | |||
| Standard Deviation | 4.17 | |||
| Variance | 17.38 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (1.07) | |||
| Treynor Ratio | 1.08 | |||
| Maximum Drawdown | 30.71 | |||
| Value At Risk | (7.75) | |||
| Potential Upside | 5.16 | |||
| Skewness | 2.14 | |||
| Kurtosis | 13.6 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | 1.09 | |||
| Mean Deviation | 2.45 | |||
| Coefficient Of Variation | (2,021) | |||
| Standard Deviation | 4.17 | |||
| Variance | 17.38 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (1.07) | |||
| Treynor Ratio | 1.08 | |||
| Maximum Drawdown | 30.71 | |||
| Value At Risk | (7.75) | |||
| Potential Upside | 5.16 | |||
| Skewness | 2.14 | |||
| Kurtosis | 13.6 |
Consider Dare Bioscience's intraday indicators
Dare Bioscience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dare Bioscience stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Dare Bioscience time-series forecasting models is one of many Dare Bioscience's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dare Bioscience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Dare Stock media impact
There is far too much social signal, news, headlines, and media speculation about Dare Bioscience that are available to investors today. This information is accessible both publicly - through Dare Bioscience's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Dare-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Dare Bioscience news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Dare Bioscience relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Dare Bioscience's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Dare Bioscience alpha.
Dare Bioscience Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Dare Bioscience can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Top Midday Gainers
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Dare Bioscience Historical Investor Sentiment
Investor biases related to Dare Bioscience's public news can be used to forecast risks associated with an investment in Dare. The trend in average sentiment can be used to explain how an investor holding Dare can time the market purely based on public headlines and social activities around Dare Bioscience. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Dare Bioscience's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Dare Bioscience and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Dare Bioscience news discussions. The higher the estimate score, the more favorable the investor's outlook on Dare Bioscience.
Dare Bioscience Corporate Management
| David Friend | Chief Officer | Profile | |
| MarDee HaringLayton | Chief Officer | Profile | |
| John Fair | Chief Business Officer | Profile | |
| Lisa WaltersHoffert | Executive Officer | Profile | |
| Mark Walters | Vice Operations | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dare Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Dare Stock refer to our How to Trade Dare Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dare Bioscience. If investors know Dare will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dare Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.17) | Revenue Per Share | Quarterly Revenue Growth 1.734 | Return On Assets | Return On Equity |
The market value of Dare Bioscience is measured differently than its book value, which is the value of Dare that is recorded on the company's balance sheet. Investors also form their own opinion of Dare Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Dare Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dare Bioscience's market value can be influenced by many factors that don't directly affect Dare Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Dare Bioscience's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Dare Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dare Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.